CRIS · Curis Inc · Executive Compensation
$0.43
-0.04 (-9.03%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 13, 2026
Market Cap
$4.06M
Shares
9.51M
Volume · Nov 20
531.09K
Avg daily vol (3M)
4.27M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jonathan Zung | Chief Development Officer | $882,415 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Diantha Duvall | Chief Financial Officer | $786,109 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| James E. Dentzer | President and Chief Executive Officer | $3,390,187 |
| William E. Steinkrauss | Chief Financial Officer | $1,899,445 |
| Robert Martell | M.D., Ph.D. Head of Research and Development | $1,502,517 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| James E. Dentzer | President and Chief Executive Officer | $1,672,849 |
| Robert Martell | M.D., Ph.D. Head of Research and Development | $961,345 |
| William E. Steinkrauss | Chief Financial Officer | $891,755 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| James E. Dentzer | President and Chief Executive Officer | $1,557,773 |
| Robert Martell | M.D., Ph.D. Head of Research and Development | $776,494 |
| William E. Steinkrauss | Chief Financial Officer | $690,165 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| James E. Dentzer | President and Chief Executive Officer | $1,964,736 |
| Robert Martell | M.D., Ph.D. Head of Research and Development | $940,469 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| James E. Dentzer | President and Chief Executive Officer | $1,578,961 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Marc Rubin, M.D. | Class II director | Appointed | 2025-05-22 |
| John A. Hohneker, M.D. | Class II director | Appointed | 2025-05-22 |
| James E. Dentzer | Class I director |
Already on the board
Since at least 2021: re-election or new board role
|
2024-05-23 |
| Anne E. Borgman, M.D. | Class I director | Appointed | 2024-05-23 |
| Lori A. Kunkel, M.D. | member of the Board of Directors | Resigned | 2022-09-22 |
| Bill Steinkrauss | Chief Financial Officer | Resigned | 2022-08-04 |
| Diantha Duvall | chief financial officer, treasurer, assistant secretary, principal financial officer and principal accounting officer | Appointed | 2022-08-04 |
|
William Steinkrauss
“Mr. Steinkrauss’s decision to leave his position at Curis is not the result of any dispute or disagreement with the Company or its Board of Directors regarding the Company’s financial reporting or disclosures, accounting policies or procedures or operating practices.”
|
Chief Financial Officer and Chief Administrative Officer (Principal Financial and Accounting Officer) | Resigned | 2022-06-30 |
| John A. Hohneker, M.D. | class II director | Appointed | 2021-12-06 |
Leadership
- James E. Dentzer CEO, Board Member
- Martyn D. Greenacre Chairman, Board Member
- William E. Steinkrauss CFO
- Anne E. Borgman Board Member
- Anne E. Borgman, M.D. Board Member
- John A. Hohneker Board Member
- John A. Hohneker, M.D. Board Member
- Kenneth I. Kaitin Board Member
- Kenneth I. Kaitin, Ph.D. Board Member
- Marc Rubin Board Member
- Marc Rubin, M.D. Board Member
Key facts
CIK
1108205
CUSIP
231269408
13F (30d)
52 filings
29 filers
Visit website
Investor relations